Aspirin Looks Good for Thromboprophylaxis Even in Patients With Risk Factors for Clotting
A robust secondary analysis of the definitive RCT on the topic is one not to miss.
What’s the Claim?
The original PREVENT CLOT trial — a robust noninferiority trial that was both well designed and well executed — was published a few months before CORRelations began and so we never covered it. Its main finding was that among patients who had surgery for pelvic or extremity fractures,
. . . thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep vein thrombosis and pulmonary embolism and low 90-day mortality
This week, we cover a nice secondary analysis of that RCT, which stratified patients by their risk of clotting and found no differences between aspirin and LMWH in terms of thromboembolic events in the low, medium, medium-high, and high risk quartiles. In terms of medication satisfaction, patients — not surprisingly — preferred aspirin to an injectable treatment.
